biostudies-literatureUnknown11D'Cruz OJ<h4>Background</h4>Overexpression of the cytokine - transforming growth factor-beta 2 (TGF-β2) - has been implicated in the malignant progression of pancreatic cancer (PAC). OT-101 (trabedersen) is an antisense oligodeoxynucleotide designed to target the human TGF-β2 mRNA. In a Phase I/II study, OT-101 treatment with subsequent chemotherapy was characterized by outstanding overall survival (OS) in patients with PAC.<h4>Objective</h4>This study sought to identify 1) co-regulated sets of cyto-/chemokines; 2) potential mechanisms that link TGF-β receptor type 2 receptor inhibition that may result in the induction of a cytokine storm; and 3) predictive biomarkers for OS outcome in OT-101-treated patients with PAC.<h4>Materials and methods</h4>Plasma levels of 31 cyto-/chemokines were tracked oOncoTargets and therapy2779-2796https://www.ebi.ac.uk/biostudies/studies/S-EPMC5957068biostudies-literatureImpact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.PMC5957068Ng KD'Cruz OJQazi STrieu VHwang LfalseImpact of targeting transforming growth factor β-2 with antisense OT-101 on the cytokine and chemokine profile in patients with advanced pancreatic cancer.<h4>Background</h4>Overexpression of the cytokine - transforming growth factor-beta 2 (TGF-β2) - has been implicated in the malignant progression of pancreatic cancer (PAC). OT-101 (trabedersen) is an antisense oligodeoxynucleotide designed to target the human TGF-β2 mRNA. In a Phase I/II study, OT-101 treatment with subsequent chemotherapy was characterized by outstanding overall survival (OS) in patients with PAC.<h4>Objective</h4>This study sought to identify 1) co-regulated sets of cyto-/chemokines; 2) potential mechanisms that link TGF-β receptor type 2 receptor inhibition that may result in the induction of a cytokine storm; and 3) predictive biomarkers for OS outcome in OT-101-treated patients with PAC.<h4>Materials and methods</h4>Plasma levels of 31 cyto-/chemokines were tracked o2018-01-01T00:00:00Z20182025-04-05T00:06:26.708Z2019-03-26T23:38:18ZS-EPMC59570682978512610.2147/OTT.S161905